Vaccine Responses in Patients With B Cell Malignancies
Status:
Recruiting
Trial end date:
2024-08-16
Target enrollment:
Participant gender:
Summary
Background:
People with B cell malignancies (blood cancers) often cannot mount a full immune response to
infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to
treat blood cancers, may also negatively affect a person s response to certain vaccines.
Researchers want to learn more about vaccine responses in people with certain types of blood
cancers. The findings may help develop better vaccine strategies for people with these
cancers.
Objective:
To learn how well vaccines work in people who have certain types of blood cancers.
Eligibility:
Adults aged 18 years or older who have chronic lymphocytic leukemia (CLL), Waldenstrom
macroglobulinemia, or certain non-Hodgkin lymphomas.
Design:
Participants will get one or more vaccines for illnesses such as COVID-19, hepatitis B, and
shingles. They can choose which vaccines they receive. They will give a blood sample before
they get each vaccine. Some vaccines require a second dose 3-6 weeks later. Participants may
give an optional blood sample with the second vaccine dose. About 4 weeks after they finish
each vaccine series, they will give another blood sample. They will have 2-3 study visits per
vaccine.
Participants may receive a booster dose for some vaccines. The booster dose is optional. They
will give another blood sample with the booster dose.
Participants will have pregnancy tests, if needed.
Participants with CLL who receive BTKis may be asked to pause treatment for up to 7 weeks.
Participants may give follow-up blood samples up to 2 times a year for 5 years. These blood
samples are optional.
Participation will last for up to 5 years after each vaccine series is received.